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ABSTRACT
Cervical cancer is a disease that remains a concern for women worldwide. 
Despite the implementation of standard Pap test and the HPV test, the screening 
coverage is still low due to its invasive nature as both involve the collection of 
cervical samples. The HPV screening test itself is expensive, extensive and label- 
dependent. In this pilot study, piezoelectric biosensor was used for HPV DNA 
detection in urine due to its non-invasive approach, simplicity, low instrumentation 
costs, and label-free detection. Urine samples were collected from 21 women with 
abnormal Pap Test results and 19 women with normal Pap Test results. HPV HR 
piezoelectric biosensor was developed for the detection of 3 high-risk HPV DNA 
strains (16, 18, and 33) and HPV 16 piezoelectric biosensor is for the detection of 
only HPV 16 DNA. Probe optimisation and calibration experiments were carried 
out. Amplified urinary DNA samples were analysed using the biosensors. Results 
showed that the optimum probe concentration for both biosensors was 1.0 |iM. The 
biosensor was able to detect the presence of complementary target DNAs with high 
specificity. For HPV HR piezoelectric biosensor, the sensitivity was 97.99 Hz |iM " 
1, the instrument detection limit was 16.36 Hz and the concentration detection limit 
was 0.10344 |iM. Meanwhile, for HPV 16 DNA piezoelectric biosensor, the 
sensitivity was 99.19 Hz |iM -1, the instrument detection limit was 15.14 Hz and the 
concentration detection limit was 0.088 |iM. The clinical sensitivity and specificity 
for both types of piezoelectric biosensor were both 100%. These preliminary results 
allow for the possibility of implementing the piezoelectric biosensor for the detection 
of urinary HPV DNA as a potential alternative screening method.
vABSTRAK
Kanser serviks adalah penyakit yang boleh dicegah, yang masih merupakan 
masalah bagi wanita di Malaysia dan di seluruh dunia. Ia disebabkan oleh jangkitan 
berterusan Human Papillomavirus (HPV) di kawasan serviks. Walaupun ujian Pap 
biasa dan ujian HPV telah diperkenalkan, liputan saringan masih rendah kerana 
kedua-dua ujian ini invasif dan memalukan. Ini disebabkan oleh pengumpulan 
sampel dilakukan di bahagian serviks. Ujian saringan HPV adalah mahal, rumit 
dan memerlukan label. Dalam kajian pilot ini, biosensor piezoelektrik digunakan 
untuk mengesan HPV DNA dalam air kencing kerana pendekatannya tidak invasif, 
mudah, kos peralatan yang rendah, boleh dipantau secara masa nyata, tidak 
memerlukan enzim dan label. 21 orang wanita yang mempunyai hasil ujian Pap 
yang tidak normal dan 19 wanita yang mempunyai hasil ujian Pap yang normal, 
telah menyertai kajian perintis ini. HPV HR biosensor piezoelektrik telah 
dibangunkan untuk mengesan 3 jenis HPV DNA berisiko tinggi (16, 18, 33) dan 
HPV 16 biosensor piezoelektrik adalah untuk mengesan hanya HPV 16 DNA. 
Pengoptimuman dan eksperimen penentukuran telah dijalankan bagi kedua-dua 
biosensor. Sampel DNA air kencing daripada peserta telah dianalisa oleh kedua-dua 
biosensor. Hasil kajian menunjukkan bahawa kepekatan prob yang optimum untuk 
kedua-dua biosensor adalah 1.0 |iM. Biosensor ini boleh mengesan kehadiran DNA 
dengan kadar pemilihan dan pengkhususan yang tinggi. Untuk HPV HR biosensor 
piezoelektrik, sensitivitinya adalah 97.99 Hz |iM -1, had pengesanan untuk alat ialah 
16.36 Hz dan had pengesanan untuk kepekatan ialah 0.10344 |iM. Sementara itu, 
bagi HPV HR biosensor piezoelektrik, sensitivitinya adalah 99.19 Hz uM-1, had 
pengesanan untuk alat ialah 15.14 Hz dan had pengesanan untuk kepekatan ialah 
0.088 |iM. Nilai sensitiviti dan pengkhususan secara klinikal untuk kedua-dua jenis 
biosensor apabila dibandingkan dengan kaedah Ujian Pap sebagai rujukan, kedua- 
duanya adalah 100%. Hasil kajian awal ini membolehkan kaedah saringan untuk 
kanser serviks boleh dilakukan secara tidak invasif dengan mengesan HPV DNA di 
dalam sampel air kencing dengan menggunakan biosensor piezoelektrik.
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C H A P T E R  1
INTRODUCTION
1.1 Background of Study
Cervical cancer or carcinoma is the second most common malignancy in 
females in the world affecting about 500,000 people every year [1]. It represents the 
third most common cause of female mortality worldwide [1][2]. In Malaysia, 
cervical cancer is the third most common malignancy in females and is the fourth 
common cause of female mortality [3]. Over the years, the worldwide incidence and 
mortality of this disease have reduced due to the implementation of Pap test. 
However, about 274,000 women still die from this disease every year [4] [5]. In 
Peninsular Malaysia, 847 cases of cervical cancer were recorded in 2006, although 
the report varied by racial groups, whereby the Indian women had the highest score, 
followed by Chinese and Malay. The incidence increased with age after 30 years and 
peaked at the age of 65 to 69 [6].
Cervical cancer is caused by persistent infection of high-risk strains of 
Human Papillomavirus (HPV) in the cervix, causing cytological changes, resulting in 
the development of malignant lesions [7]. The process involves the integration of the 
viral DNA into the human host cell genome [7]. It has been proven that early 
detection or screening of precancerous lesions, managed to prevent cervical cancer 
disease [1]. In addition to the screening, HPV vaccinations have also been
2implemented as a primary prevention strategy for the infection and other related 
diseases [1].
1.2 Problem Statem ent
Cervical cancer screening tests are important to detect pre-cancerous changes 
in the cervical squamous cells, so that, cervical cancer can be prevented from 
developing by early medical or surgical intervention. Although these tests have 
managed to reduce the cervical cancer incidence worldwide, they still have 
limitations that can be potentially improved in the future.
The standard cervical cancer screening is usually done through Pap test by 
cytological procedure. However, this test causes variability in the result 
interpretation as it depends on visual evaluation by different experts. The molecular- 
based screening tests use PCR and hybrid capture techniques to detect the presence 
of HPV DNA in samples. Nevertheless, the PCR-method is complicated as it 
involves labelling approach using enzymes, fluorophores, and radioactivity. 
Moreover, this test is associated with cross-reaction and cross-hybridisation which 
results in less accurate results. Apart from that, both cytology and molecular-based 
screening tests are invasive which causes discomfort for patients, as these tests 
require pelvic examination using a speculum to collect samples from the cervical 
area. In addition to these, all the tests require extensive procedures and expensive 
instrumentations.
In order to overcome the above limitations, in this research, the use of 
simpler, cheaper, quantitative and label-free technique using piezoelectric biosensor 
was used to detect the presence of HPV DNA in urine, which involves a non- 
invasive and pain-free sampling method. Probe optimisation experiment for the 
biosensor was necessary to know the optimum probe concentration. Calibration
3experiment was also required to confirm that the biosensor is an acceptable 
instrument for HPV DNA detection. Lastly, the biosensor had to be tested whether 
it could detect HPV DNA in the real clinical urine samples and the result should be 
compared to the detection by PCR.
1.3 Study Objectives
This study aims to investigate the appropriate probe concentration for 
immobilisation reaction on the Quartz Crystal Microbalance (QCM) gold electrode 
of the piezoelectric biosensor. It also aims to calibrate the HPV DNA biosensor 
using different synthetic target DNA concentrations which was never done by any 
studies before. Furthermore, this study aims to investigate the ability of the 
biosensor to detect HPV DNA in real urine samples from patients.
1.4 Study Scope
In this study, two types of piezoelectric biosensors were tested for the HPV 
DNA detection. Type 1 (HPV HR) is for screening positive samples of 3 high-risk 
HPV strains namely HPV 16, 18, and 33, using a degenerate probe. Meanwhile, 
Type 2 (HPV 16) is for the detection of only HPV 16 DNA. The HPV HR biosensor 
allows fast detection or screening of the virus presence, without identifying the 
particular strain involved. Ideally, only if the samples are identified positive from 
the first screening, they need to undergo subsequent analysis using the HPV 16 
biosensor for genotyping of specifically HPV 16 strain, which is the main culprit of 
cervical cancer. These two steps aim to reduce cost and analysis time.
Urine samples were collected from female subjects who have been sexually 
exposed and have had positive Pap Test results which include atypical squamous
4cells, low-grade squamous intraepithelial lesion (LSIL) or high-grade squamous 
intraepithelial lesion (HSIL).
To achieve the objectives, series of experiments were conducted which 
involve probe optimisation, biosensor calibration study, determination of the limit of 
detection, reusability of the biosensor, and the ability of the biosensor to detect HPV 
DNA in clinical urine sample.
1.5 Significance of Study
This study is important as it calibrated the HPV DNA piezoelectric biosensor 
accordingly, so that it could be a valid instrument to be used in the real clinical 
settings using real clinical urine samples. The optimum concentration of biotinylated 
probe as well as the optimum concentration of target DNA was also determined in 
this study.
The outcome of this research project will improve the number of females 
attending for cervical cancer screening test as it introduces an alternative non- 
invasive and simpler screening test. This will eventually improve the diagnostic and 
prognostic procedure of detecting cervical cancer at early stage so that early effective 
intervention for the disease can be made. Furthermore, this study will improve the 
worldwide and the national healthcare service for patients. In addition, this study 
will help to increase the number of national publication, thus contributing to the 
national medical research.
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